Cargando…

Potential Effect of a Selective Peroxisome Proliferator-activated Receptor Alpha Modulator on Metabolic Dysfunction-associated Fatty Liver Disease

Detalles Bibliográficos
Autores principales:	Kamimura, Hiroteru, Kimura, Atsushi, Terai, Shuji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8355382/ https://www.ncbi.nlm.nih.gov/pubmed/33612688 http://dx.doi.org/10.2169/internalmedicine.6906-20

Ejemplares similares

Rapid Onset of Weight Gain and Liver Dysfunction Successfully Treated With Nutrition and Exercise
por: Kamimura, Hiroteru, et al.
Publicado: (2021)

Involvement of the liver-gut peripheral neural axis in nonalcoholic fatty liver disease pathologies via hepatic HTR2A
por: Owaki, Takashi, et al.
Publicado: (2022)

Considerations of elderly factors to manage the complication of liver cirrhosis in elderly patients
por: Kamimura, Kenya, et al.
Publicado: (2019)

Rare complication of hepatocellular carcinoma in Wilson's disease
por: Ohkoshi‐Yamada, Marina, et al.
Publicado: (2021)

Modulation of serotonin in the gut-liver neural axis ameliorates the fatty and fibrotic changes in non-alcoholic fatty liver
por: Ko, Masayoshi, et al.
Publicado: (2021)

Specific Gastric Blood Vessels in Sinistral Portal Hypertension
por: Kamimura, Hiroteru, et al.
Publicado: (2017)

Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?
por: Fruchart, Jean-Charles, et al.
Publicado: (2021)

Correction: Modulation of serotonin in the gut-liver neural axis ameliorates the fatty and fibrotic changes in non-alcoholic fatty liver
por: Ko, Masayoshi, et al.
Publicado: (2023)

Small Intestinal Bacterial Overgrowth Diagnosed by a Breath Test and Improved by Rifaximin in a Patient with Hepatic Encephalopathy and Alcoholic Liver Cirrhosis
por: Sakamaki, Akira, et al.
Publicado: (2020)

Hepatic Peroxisome Proliferator-Activated Receptor Alpha Dysfunction in Porcine Septic Shock
por: Vandewalle, Jolien, et al.
Publicado: (2022)

Peroxisome Proliferator-Activated Receptors Associated with Nonalcoholic Fatty Liver Disease
por: Wang, Nan, et al.
Publicado: (2017)

Metabolic adaptation to intermittent fasting is independent of peroxisome proliferator-activated receptor alpha
por: Li, Guolin, et al.
Publicado: (2017)

Metabolic Dysfunction and Peroxisome Proliferator-Activated Receptors (PPAR) in Multiple Sclerosis
por: Ferret-Sena, Véronique, et al.
Publicado: (2018)

Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis
por: Honda, Yasushi, et al.
Publicado: (2017)

Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders
por: Cho, Min-Chul, et al.
Publicado: (2008)

Long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients: Patient-reported outcome based analyses
por: Kamimura, Kenya, et al.
Publicado: (2017)

Peroxisome Proliferator-Activated Receptor Alpha Target Genes
por: Rakhshandehroo, Maryam, et al.
Publicado: (2010)

Antiprogramed cell death‐1 therapy with microspheres for metastatic liver tumors
por: Kamimura, Hiroteru, et al.
Publicado: (2019)

Different distribution of mucosal-associated invariant T cells within the human cecum and colon
por: Hama, Isamu, et al.
Publicado: (2019)

Interactions between Human Liver Fatty Acid Binding Protein and Peroxisome Proliferator Activated Receptor Selective Drugs
por: Velkov, Tony
Publicado: (2013)

Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia
por: Fruchart, Jean-Charles
Publicado: (2017)

Selective peroxisome proliferator‐activated receptor‐α modulator K‐877 efficiently activates the peroxisome proliferator‐activated receptor‐α pathway and improves lipid metabolism in mice
por: Takei, Kenta, et al.
Publicado: (2017)

Renal Impairment in Chronic Hepatitis B: A Review
por: Kamimura, Hiroteru, et al.
Publicado: (2018)

Activation of peroxisome proliferator-activated receptor-alpha stimulates both differentiation and fatty acid oxidation in adipocytes
por: Goto, Tsuyoshi, et al.
Publicado: (2011)

Cyclin D1 represses peroxisome proliferator-activated receptor alpha and inhibits fatty acid oxidation
por: Kamarajugadda, Sushama, et al.
Publicado: (2016)

Peroxisome proliferator-activated receptor-alpha activation and dipeptidyl peptidase-4 inhibition target dysbiosis to treat fatty liver in obese mice
por: Silva-Veiga, Flavia Maria, et al.
Publicado: (2022)

Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists
por: Fruchart, Jean-Charles
Publicado: (2013)

Molecular Mechanisms and Treatment of Sarcopenia in Liver Disease: A Review of Current Knowledge
por: Kamimura, Hiroteru, et al.
Publicado: (2021)

Use of a Deep Learning Approach for the Sensitive Prediction of Hepatitis B Surface Antigen Levels in Inactive Carrier Patients
por: Kamimura, Hiroteru, et al.
Publicado: (2022)

Adaptation of peroxisome proliferator-activated receptor alpha to hibernation in bats
por: Han, Yijie, et al.
Publicado: (2015)

Activation of peroxisome proliferator activated receptor alpha ameliorates ethanol mediated liver fibrosis in mice
por: Nan, Yue-Min, et al.
Publicado: (2013)

Rational arrangement of measuring shear wave speed in the liver
por: Yokoo, Takeshi, et al.
Publicado: (2019)

Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease
por: Nakajima, Atsushi, et al.
Publicado: (2021)

Kinetic characterization of selective peroxisome-proliferator-activated receptor gamma modulators in vitro
por: Knape, T, et al.
Publicado: (2012)

The prognosis and incidence of hepatic encephalopathy of patients with liver cirrhosis treated with proton pump inhibitors: A multicenter retrospective study in Japan
por: Sakamaki, Akira, et al.
Publicado: (2021)

A role of peroxisome proliferator‐activated receptor γ in non‐alcoholic fatty liver disease
por: Skat‐Rørdam, Josephine, et al.
Publicado: (2019)

Peroxisome Proliferator Activated Receptors and Lipoprotein Metabolism
por: Kersten, Sander
Publicado: (2008)

Diagnosis and management of fibromuscular dysplasia and segmental arterial mediolysis in gastroenterology field: A mini-review
por: Ko, Masayoshi, et al.
Publicado: (2018)

Changes in peroxisome proliferator-activated receptor alpha target gene expression in peripheral blood mononuclear cells associated with non-alcoholic fatty liver disease
por: Li, Tian Tian, et al.
Publicado: (2018)

Transplacental induction of fatty acid oxidation in term fetal pigs by the peroxisome proliferator-activated receptor alpha agonist clofibrate
por: Lin, Xi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_00l4uugu8rdpj9i6h3l1cs2n0a